Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 180

1.

[Mechanisms of resistance to CYP17A1 inhibitors in castrate resistant prostate cancer].

Ripert T, Crouzet S, Ploussard G, De La Taille A, Robert G.

Prog Urol. 2013 Oct;23 Suppl 1:S16-22. doi: 10.1016/S1166-7087(13)70042-3. Review. French.

PMID:
24314735
2.

Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer.

Rehman Y, Rosenberg JE.

Drug Des Devel Ther. 2012;6:13-8. doi: 10.2147/DDDT.S15850. Epub 2012 Jan 16. Review.

3.

[Prostate cancer and new hormonal treatments: mechanism of action and main clinical results].

Neuzillet Y, Flamand V, Lebdai S, Villers A, Lebret T.

Prog Urol. 2013 Oct;23 Suppl 1:S34-43. doi: 10.1016/S1166-7087(13)70044-7. Review. French.

PMID:
24314737
4.

Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer.

Stein MN, Patel N, Bershadskiy A, Sokoloff A, Singer EA.

Asian J Androl. 2014 May-Jun;16(3):387-400. doi: 10.4103/1008-682X.129133. Review.

5.

[CYP17A1 inhibitors in prostate cancer: mechanisms of action independent of the androgenic pathway].

Audenet F, Murez T, Ripert T, Villers A, Neuzillet Y.

Prog Urol. 2013 Oct;23 Suppl 1:S9-15. doi: 10.1016/S1166-7087(13)70041-1. Review. French.

PMID:
24314739
6.

Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis.

Yuan X, Cai C, Chen S, Chen S, Yu Z, Balk SP.

Oncogene. 2014 May 29;33(22):2815-25. doi: 10.1038/onc.2013.235. Epub 2013 Jun 10. Review.

7.

Pre-chemotherapy abiraterone acetate. A proposal of a treatment algorithm in castration resistant prostate cancer.

Arrabal-Martín M, Anglada-Curado F, Cózar-Olmo JM, Soler-Martínez J, Moreno-Jiménez J, Castiñeiras-Fernández J, Ledo-Cepero MJ, Beardo-Villar P, Requena-Tapia MJ, Zuluaga-Gómez A; Grupo AAyEU.

Actas Urol Esp. 2014 Jun;38(5):327-33. doi: 10.1016/j.acuro.2013.10.008. Epub 2013 Dec 15. Review. English, Spanish.

PMID:
24342031
8.

Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer.

Leibowitz-Amit R, Templeton AJ, Omlin A, Pezaro C, Atenafu EG, Keizman D, Vera-Badillo F, Seah JA, Attard G, Knox JJ, Sridhar SS, Tannock IF, de Bono JS, Joshua AM.

Ann Oncol. 2014 Mar;25(3):657-62. doi: 10.1093/annonc/mdt581. Epub 2014 Jan 23.

9.

Metabolic and prostate-specific antigen response after abiraterone acetate withdrawal: a new clinical scenario for castration-resistant prostate cancer?

Caffo O, Palermo A, Veccia A, Maines F, Chierichetti F, Galligioni E.

Clin Genitourin Cancer. 2013 Dec;11(4):e10-4. doi: 10.1016/j.clgc.2013.04.021. Epub 2013 Jun 27. No abstract available.

PMID:
23810439
10.

Abiraterone acetate, a first-in-class CYP17 inhibitor, establishes a new treatment paradigm in castration-resistant prostate cancer.

Bedoya DJ, Mitsiades N.

Expert Rev Anticancer Ther. 2012 Jan;12(1):1-3. doi: 10.1586/era.11.196. No abstract available.

PMID:
22149426
11.

Enzalutamide versus abiraterone acetate for the treatment of men with metastatic castration-resistant prostate cancer.

Zhang T, Zhu J, George DJ, Armstrong AJ.

Expert Opin Pharmacother. 2015 Mar;16(4):473-85. doi: 10.1517/14656566.2015.995090. Epub 2014 Dec 23. Review.

PMID:
25534660
12.

Androgen receptors in hormone-dependent and castration-resistant prostate cancer.

Shafi AA, Yen AE, Weigel NL.

Pharmacol Ther. 2013 Dec;140(3):223-38. doi: 10.1016/j.pharmthera.2013.07.003. Epub 2013 Jul 13. Review.

PMID:
23859952
13.

Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants.

Mostaghel EA, Marck BT, Plymate SR, Vessella RL, Balk S, Matsumoto AM, Nelson PS, Montgomery RB.

Clin Cancer Res. 2011 Sep 15;17(18):5913-25. doi: 10.1158/1078-0432.CCR-11-0728. Epub 2011 Aug 1.

15.

[ASC-J9 for castration-resistant prostate cancer].

Yamashita S, Arai Y.

Nihon Rinsho. 2014 Dec;72(12):2126-9. Japanese.

PMID:
25518345
16.

Abiraterone acetate: in metastatic castration-resistant prostate cancer.

Yang LP.

Drugs. 2011 Oct 22;71(15):2067-77. doi: 10.2165/11208080-000000000-00000. Erratum in: Drugs. 2012 Jan 22;72(2):192.

PMID:
21985170
17.

Abiraterone acetate: targeting persistent androgen dependence in castration-resistant prostate cancer.

Harshman LC, Taplin ME.

Adv Ther. 2013 Aug;30(8):727-47. doi: 10.1007/s12325-013-0050-3. Epub 2013 Aug 27. Review.

18.

Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors.

Chen EJ, Sowalsky AG, Gao S, Cai C, Voznesensky O, Schaefer R, Loda M, True LD, Ye H, Troncoso P, Lis RL, Kantoff PW, Montgomery RB, Nelson PS, Bubley GJ, Balk SP, Taplin ME.

Clin Cancer Res. 2015 Mar 15;21(6):1273-80. doi: 10.1158/1078-0432.CCR-14-1220. Epub 2014 Oct 15.

19.

Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial.

Logothetis CJ, Basch E, Molina A, Fizazi K, North SA, Chi KN, Jones RJ, Goodman OB, Mainwaring PN, Sternberg CN, Efstathiou E, Gagnon DD, Rothman M, Hao Y, Liu CS, Kheoh TS, Haqq CM, Scher HI, de Bono JS.

Lancet Oncol. 2012 Dec;13(12):1210-7. doi: 10.1016/S1470-2045(12)70473-4. Epub 2012 Nov 9.

PMID:
23142059
20.

Mechanisms of drug resistance that target the androgen axis in castration resistant prostate cancer (CRPC).

Penning TM.

J Steroid Biochem Mol Biol. 2015 Sep;153:105-13. doi: 10.1016/j.jsbmb.2015.05.010. Epub 2015 May 29. Review.

Supplemental Content

Support Center